Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
0.2700
Dollar change
+0.0088
Percentage change
3.37
%
Index- P/E- EPS (ttm)-1.56 Insider Own56.52% Shs Outstand11.00M Perf Week-17.93%
Market Cap3.00M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.83M Perf Month-11.53%
Income-16.37M PEG- EPS next Q- Inst Own1.41% Short Float1.73% Perf Quarter-36.47%
Sales1.26M P/S2.38 EPS this Y- Inst Trans-35.16% Short Ratio0.47 Perf Half Y-55.97%
Book/sh-1.15 P/B- EPS next Y- ROA-81.16% Short Interest0.08M Perf Year-86.29%
Cash/sh0.03 P/C10.33 EPS next 5Y- ROE-176.68% 52W Range0.25 - 2.42 Perf YTD-44.10%
Dividend Est.- P/FCF- EPS past 5Y-8.00% ROI-118.43% 52W High-88.84% Beta0.30
Dividend TTM- Quick Ratio0.10 Sales past 5Y-4.02% Gross Margin16.15% 52W Low8.00% ATR (14)0.04
Dividend Ex-Date- Current Ratio0.10 EPS Y/Y TTM-23.61% Oper. Margin-571.96% RSI (14)38.50 Volatility13.56% 13.16%
Employees5 Debt/Eq1.15 Sales Y/Y TTM4.45% Profit Margin-1303.47% Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.88 EPS Q/Q-269.72% Payout- Rel Volume0.11 Prev Close0.26
Sales Surprise- EPS Surprise- Sales Q/Q8.43% Earnings- Avg Volume175.75K Price0.27
SMA20-13.27% SMA50-22.93% SMA200-60.03% Trades Volume19,122 Change3.37%
Apr-22-24 09:00AM
Apr-16-24 09:52AM
Mar-28-24 09:00AM
Dec-18-23 09:00AM
Oct-18-23 09:00AM
09:00AM Loading…
Oct-04-23 09:00AM
Sep-13-23 09:15AM
Sep-05-23 08:00AM
Aug-30-23 10:45AM
09:00AM
Aug-21-23 09:00AM
Jul-24-23 09:00AM
Jul-19-23 09:00AM
Jul-10-23 09:00AM
Apr-27-23 09:00AM
09:00AM Loading…
Apr-17-23 09:00AM
Apr-11-23 09:00AM
Mar-03-23 09:00AM
Feb-13-23 09:00AM
Jan-17-23 09:00AM
Jan-11-23 09:00AM
Jan-03-23 09:00AM
Dec-14-22 09:00AM
Dec-12-22 09:00AM
Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.